Clinical application of long-read sequencing in newborn genetic screening for congenital adrenal hyperplasia.

Authors

Peiran Zhao, Xiaolong Qiu, Qingying Lin, Ting Huang, Yinglin Zeng, Jinfu Zhou, Liangpu Xu

Published in

Frontiers in genetics. Volume 17. Pages 1894466. Epub Aug 10, 2026.

Abstract

Screening for congenital adrenal hyperplasia (CAH) relying solely on 17α-hydroxyprogesterone (17α-OHP) presents limited diagnostic performance, highlighting an urgent need to develop more robust screening strategies for neonates.
We conducted retrospective and prospective cohort studies to explore the clinical applicability of long-read sequencing (LRS) in CAH genetic testing within primary and secondary newborn screening (NBS) systems, respectively. The retrospective cohort comprised 100,145 neonates who underwent routine 17α-OHP primary CAH screening at the Fujian Provincial Newborn Screening Center from January 1 to December 31, 2019. Among these infants, 52 full-term screen-positive neonates received further LRS-based CAH genotyping. The prospective cohort enrolled 2,100 newborns recruited from Fujian Maternity and Child Health Hospital between May 1 and May 31, 2023, who underwent simultaneous 17α-OHP measurement and LRS-mediated CAH genetic analysis.
In the retrospective cohort, the positive rate of 17α-OHP screening was 0.19% (190/100,145, 95% CI: 0.17%-0.21%), and five infants were definitively diagnosed with CAH, corresponding to a disease prevalence of 1:20,029. LRS genotyping successfully identified five neonates harboring pathogenic CYP21A2 mutations consistent with confirmed genetic diagnosis. In this prospective cohort study, two newborns (1/1050) with normal 17α-OHP concentrations were found to carry biallelic pathogenic variants in the CYP21A2 gene. In addition, 88 neonates (4.2%) with normal 17α-OHP levels were found to carry heterozygous CAH-related variants. Among these heterozygotes, 85 individuals harbored CYP21A2 variants, representing 32 distinct genotypes. The calculated carrier frequencies were 1 in 78 for classic CAH and 1 in 40 for non-classic CAH.
LRS-integrated genetic newborn screening exhibits favorable efficacy for CAH identification. This combined screening modality holds great promise for wide implementation in routine neonatal screening practice.

PMID:
42634743
Bibliographic data and abstract were imported from PubMed on 24 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.